Forebyggelse af herpes zoster med vaccination

Kristian Kofoed; Finn Rønholt; Jan Gerstoft; Carsten Sand

Forebyggelse af herpes zoster med vaccination

Translated title of the contribution: [Prevention of herpes zoster by vaccination]

Kristian Kofoed, Finn Rønholt, Jan Gerstoft, Carsten Sand

2 Citations (Scopus)

Abstract

Herpes zoster (HZ) and post-herpetic neuralgia (PHN) are frequently occurring diseases in elderly and in immuno-compromised persons. The live attenuated HZ vaccine boosts an existing immune response, so that the already established varicella-zoster virus infection is kept latent. Vaccination has been shown to halve the risk of HZ, and the risk of PHN is reduced by two thirds in people = 60 years. The vaccine is approved for persons aged = 50 years. However, the clinical efficacy of the vaccine is best studied in people aged = 60 years. The vaccine has so far not shown any serious side-effects.

Translated title of the contribution	[Prevention of herpes zoster by vaccination]
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	173
Issue number	2
Pages (from-to)	110-4
Number of pages	5
ISSN	0041-5782
Publication status	Published - 10 Jan 2011

Cite this

@article{e4e5b705cd9e4edaaff7e08719811bfd,

title = "Forebyggelse af herpes zoster med vaccination",

abstract = "Herpes zoster (HZ) and post-herpetic neuralgia (PHN) are frequently occurring diseases in elderly and in immuno-compromised persons. The live attenuated HZ vaccine boosts an existing immune response, so that the already established varicella-zoster virus infection is kept latent. Vaccination has been shown to halve the risk of HZ, and the risk of PHN is reduced by two thirds in people = 60 years. The vaccine is approved for persons aged = 50 years. However, the clinical efficacy of the vaccine is best studied in people aged = 60 years. The vaccine has so far not shown any serious side-effects.",

keywords = "Aged, Cost-Benefit Analysis, Herpes Zoster, Herpes Zoster Vaccine, Humans, Immunocompromised Host, Middle Aged, Neuralgia, Postherpetic, Risk Factors, Treatment Outcome",

author = "Kristian Kofoed and Finn R{\o}nholt and Jan Gerstoft and Carsten Sand",

year = "2011",

month = jan,

day = "10",

language = "Dansk",

volume = "173",

pages = "110--4",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske L{\ae}geforening",

number = "2",

}

TY - JOUR

T1 - Forebyggelse af herpes zoster med vaccination

AU - Kofoed, Kristian

AU - Rønholt, Finn

AU - Gerstoft, Jan

AU - Sand, Carsten

PY - 2011/1/10

Y1 - 2011/1/10

N2 - Herpes zoster (HZ) and post-herpetic neuralgia (PHN) are frequently occurring diseases in elderly and in immuno-compromised persons. The live attenuated HZ vaccine boosts an existing immune response, so that the already established varicella-zoster virus infection is kept latent. Vaccination has been shown to halve the risk of HZ, and the risk of PHN is reduced by two thirds in people = 60 years. The vaccine is approved for persons aged = 50 years. However, the clinical efficacy of the vaccine is best studied in people aged = 60 years. The vaccine has so far not shown any serious side-effects.

AB - Herpes zoster (HZ) and post-herpetic neuralgia (PHN) are frequently occurring diseases in elderly and in immuno-compromised persons. The live attenuated HZ vaccine boosts an existing immune response, so that the already established varicella-zoster virus infection is kept latent. Vaccination has been shown to halve the risk of HZ, and the risk of PHN is reduced by two thirds in people = 60 years. The vaccine is approved for persons aged = 50 years. However, the clinical efficacy of the vaccine is best studied in people aged = 60 years. The vaccine has so far not shown any serious side-effects.

KW - Aged

KW - Cost-Benefit Analysis

KW - Herpes Zoster

KW - Herpes Zoster Vaccine

KW - Humans

KW - Immunocompromised Host

KW - Middle Aged

KW - Neuralgia, Postherpetic

KW - Risk Factors

KW - Treatment Outcome

UR - https://www.scopus.com/pages/publications/78751548134

M3 - Tidsskriftartikel

C2 - 21219841

SN - 0041-5782

VL - 173

SP - 110

EP - 114

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 2

ER -

Forebyggelse af herpes zoster med vaccination

Abstract

Other files and links

Fingerprint

Cite this